Equillium, Inc. to Post Q3 2024 Earnings of $0.50 Per Share, Leerink Partnrs Forecasts (NASDAQ:EQ)

Equillium, Inc. (NASDAQ:EQFree Report) – Equities research analysts at Leerink Partnrs issued their Q3 2024 EPS estimates for shares of Equillium in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of $0.50 for the quarter. The consensus estimate for Equillium’s current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Equillium’s Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.32 EPS and FY2025 earnings at ($0.23) EPS.

Equillium (NASDAQ:EQGet Free Report) last announced its earnings results on Wednesday, November 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $8.87 million during the quarter, compared to analyst estimates of $8.85 million. Equillium had a negative net margin of 19.28% and a negative return on equity of 29.28%.

Separately, HC Wainwright decreased their target price on shares of Equillium from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, December 26th.

Check Out Our Latest Analysis on EQ

Equillium Stock Up 20.3 %

Shares of EQ opened at $1.48 on Wednesday. The firm has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.71. The firm has a market capitalization of $51.98 million, a PE ratio of -6.17 and a beta of 1.12. Equillium has a 52-week low of $0.45 and a 52-week high of $1.68.

Hedge Funds Weigh In On Equillium

Several large investors have recently made changes to their positions in the business. State Street Corp lifted its stake in Equillium by 13.2% during the first quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after buying an additional 6,564 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Equillium in the first quarter worth approximately $47,000. Renaissance Technologies LLC purchased a new stake in shares of Equillium in the second quarter worth approximately $34,000. Dimensional Fund Advisors LP purchased a new stake in shares of Equillium in the third quarter worth approximately $43,000. Finally, Integrated Wealth Concepts LLC lifted its position in shares of Equillium by 56.7% in the fourth quarter. Integrated Wealth Concepts LLC now owns 31,339 shares of the company’s stock worth $33,000 after purchasing an additional 11,339 shares in the last quarter. Institutional investors own 28.70% of the company’s stock.

About Equillium

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

Recommended Stories

Earnings History and Estimates for Equillium (NASDAQ:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.